GLP-1 receptor agonists — the drug class including semaglutide and liraglutide — appear to reduce risk across at least six obesity-related cancers: prostate, breast, pancreatic, gynecological, glioma, and oral squamous cell carcinoma. The protective mechanisms operate through both weight-dependent pathways and direct molecular actions on insulin signaling, chronic inflammation, and cellular proliferation — suggesting the drugs do more than simply reduce adipose tissue. Critically, medullary thyroid carcinoma signals seen in rodent models have not materialized in human data, and early pancreatitis and pancreatic cancer concerns have been substantially walked back by subsequent rigorous analyses.
This review arrives at an inflection point. With GLP-1 prescriptions exploding globally — semaglutide alone is projected to reach hundreds of millions of users — even modest oncologic benefit could translate into enormous population-level impact. What makes this particularly compelling is the weight-independent anti-tumor signaling: GLP-1 receptors are expressed on multiple tumor cell lines, opening a pharmacological pathway distinct from simple metabolic improvement. However, the evidence base remains almost entirely observational and secondary — no large-scale RCT has yet used cancer incidence as a primary endpoint. This is a consequential gap. Confounding by indication, healthy-user bias, and short follow-up windows plague the current literature. Until adequately powered, cancer-focused trials report, clinicians should view these signals as hypothesis-generating rather than practice-changing. Incremental but genuinely exciting.
